glp-1 receptor agonist pancreatitis risk meta-analysis Frontiers Frontiers | GLP-1 Receptor Agonists:

GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy

Evidence Level: Grade B) (99)

In addition to routine treatments, patients in the LC group daily received 1 g LC tablet for seven consecutive days

Well-structured treatments lasting 6-12 months with appropriate concentrations typically maintain noticeable improvements over pre-treatment baseline including reduced fine lines (though not eliminated as during peak treatment), improved skin texture and firmness (though less dramatic than treatment peak), better overall skin quality and appearance (though aging continues at normal rates), and resolved specific issues like scarring or hyperpigmentation (which typically remain improved permanently if successfully treated)